Videos

Andre Harvin, PharmD, MS, executive director of Pharmacy, Oncology Services at Cone Health, discusses the importance of putting precision medicine programs into oncology practices with pharmacists leading the way.

Heather N. Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICOS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.

Dr Ryan Haumschild, PharmD, MS, MBA, leads a discussion focused on HR-positive, HER2-negative treatment in advanced-stage breast cancer.

Amy Woodard, PharmD, BCOP, the steering committee co-chair of the 2022 ATOPP Summit, highlights key topics and discussions at the in-person summit in July in San Diego, CA.

Paul Feuerstadt, MD, FACG, AGAF, discussed research into the novel C. difficile treatment RBX2660 and what investigators have found about its efficacy in key subgroup analyses.

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses some common challenges hematology oncology pharmacists face in the field during their pursuit of professional growth and development.

With many ambiguous policies, pharmacists should refer to their State Boards of Pharmacy for guidance and should consider HIPAA implications.

Elizabeth Ruzzo, PhD, founder and CEO of Adyn, discusses the impact of the reversal of Roe v. Wade and how it will affect pharmacies.

Ryan Haumschild, PharmD, MS, MBA, leads a discussion regarding the treatment of relapsed/refractory mantle cell lymphoma in the presence of comorbidities.

Preetesh Jain, MBBS, MD, DM, PhD, offers perspective on unmet needs in treatment of patients with relapsed/refractory mantle cell lymphoma.

Medical experts elaborate on the AG221-AML-005 and AGILE studies and their results, as well as how we assess first-line treatment response.

Cole McCoy, PharmD, and Dr James McCloskey explain first-line treatment options for different types of AML, how genetic mutation affect treatment decisions, and the treatment option for patients with AML that are unfit for intensive chemotherapy.

June 27 is National HIV Testing Day, so Pharmacy Times® sat down with Brad McElya, PharmD, director of Specialty Health Solutions at Walgreens, to discuss the importance of HIV testing.

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

Andrea Iannucci, PharmD, BCOP, member of the Board of Directors of the Hematology/Oncology Pharmacy Association (HOPA), discusses how HOPA works within and its impact on hematology/oncology pharmacy practice management.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses his research investigating the persistence of taste and smell loss among patients who have been infected and reinfected with COVID-19.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses how patients who have experienced a loss of taste and smell following COVID-19 infection may be impacted by this symptom for years without realizing it.

Two medical professionals reveal what factors into intensive chemotherapy consideration and common toxicities found when undergoing treatment.

Cole McCoy, PharmD, shares recent changes in the AML treatment landscape, including updates to the NCCN guidelines.

Drs Preetesh Jain and Michael Wang exchange insights regarding the current and prospective treatment options for patients with Mantle Cell Lymphoma.

Dr Haumschild, PharmD, MS, MBA leads a panel of experts identifying characteristics unique to MCL and addressing initial treatment strategies.

Anna Pham, PharmD, PGY2 ambulatory care resident at Intermountain Healthcare, discusses the role of ambulatory care pharmacists in primary care clinics.

The ATHENA-MONO trial is investigating the use of rucaparib as front line maintenance treatment in ovarian cancer.

Aimee Banks, PharmD, BCPS, MSCS, clinical pharmacist in the Multiple Sclerosis Clinic at Vanderbilt University Medical Center, discusses the role of the pharmacists in patient care, improving outcomes, and managing transitions of care.

Expanded glomerular filtration rate (GFR) testing in the United States could be one step toward minimizing disparities in renal formulas, Beumer said.

The step-up dosing approach with glofitamab in a phase 1 trial enabled researchers to minimize cytokine release syndrome while maximizing outcomes.

Jeff Betcher, BSPharm, MBA, director of pharmacy at Mayo Clinic in Arizona, discusses how automated chemotherapy dose rounding can help decrease drug waste and cost.

Tina Saleh, PharmD, PGY1 specialty pharmacy resident at the University of Illinois Hospital and Health Science System, discusses how oral anticancer agents differ from infusions and how pharmacists can improve tolerability for patients.

Cole McCoy, PharmD, and James McCloskey, MD, explain common treatment goals, cytogenetic tests, and considerations that factor into choosing individualized treatment for patients with AML.